Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with Ra: Proof of Concept.

We retrospectively evaluated the utility of Ga-PSMA-11 PET for planning RaCl therapy of patients with metastatic prostate cancer and its impact on the therapeutic response as determined by prostate-specific antigen (PSA) and alkaline phosphatase (ALP), as well as the correlation of PSA changes with the results of prostate-specific membrane antigen (PSMA) PET follow-up scans. Sixty-three patients with a median age of 73 y who underwent 307 cycles of therapy with RaCl were analyzed. In 31 patients, bone scanning and radiologic imaging were performed for pretherapeutic imaging (group 1).